214 related articles for article (PubMed ID: 25641608)
1. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.
Zhang Z; Su P; Li X; Song T; Chai G; Yu X; Zhang K
Arch Pharm (Weinheim); 2015 Feb; 348(2):89-99. PubMed ID: 25641608
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
3. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
[TBL] [Abstract][Full Text] [Related]
4. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors.
Wang Z; Xu W; Song T; Guo Z; Liu L; Fan Y; Wang A; Zhang Z
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 27911011
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis.
He N; Liu P; Wang Z; Guo Z; Yan X; Chen H; Zhang Z
Biochem Biophys Res Commun; 2019 May; 512(4):921-926. PubMed ID: 30928099
[TBL] [Abstract][Full Text] [Related]
8. Design and application of a rigid quinazolone scaffold based on two-face Bim α-helix mimicking.
Zhang Z; Liang X; Li X; Song T; Chen Q; Sheng H
Eur J Med Chem; 2013 Nov; 69():711-8. PubMed ID: 24095762
[TBL] [Abstract][Full Text] [Related]
9. Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain.
Li X; Wang Z; Feng Y; Song T; Su P; Chen C; Chai G; Yang Y; Zhang Z
Chembiochem; 2014 Jun; 15(9):1280-5. PubMed ID: 24838655
[TBL] [Abstract][Full Text] [Related]
10. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
11. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
13. Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
Zhang Z; Liu C; Li X; Song T; Wu Z; Liang X; Zhao Y; Shen X; Chen H
Eur J Med Chem; 2013 Feb; 60():410-20. PubMed ID: 23314054
[TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Bruncko M; Wang L; Sheppard GS; Phillips DC; Tahir SK; Xue J; Erickson S; Fidanze S; Fry E; Hasvold L; Jenkins GJ; Jin S; Judge RA; Kovar PJ; Madar D; Nimmer P; Park C; Petros AM; Rosenberg SH; Smith ML; Song X; Sun C; Tao ZF; Wang X; Xiao Y; Zhang H; Tse C; Leverson JD; Elmore SW; Souers AJ
J Med Chem; 2015 Mar; 58(5):2180-94. PubMed ID: 25679114
[TBL] [Abstract][Full Text] [Related]
15. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.
Hedir S; De Giorgi M; Fogha J; De Pascale M; Weiswald LB; Brotin E; Marekha B; Denoyelle C; Denis C; Suzanne P; Gautier F; Juin P; Ligat L; Lopez F; Carlier L; Legay R; Bureau R; Rault S; Poulain L; Oliveira Santos JS; Voisin-Chiret AS
Eur J Med Chem; 2018 Nov; 159():357-380. PubMed ID: 30308410
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
18. 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
Song T; Li X; Chang X; Liang X; Zhao Y; Wu G; Xie S; Su P; Wu Z; Feng Y; Zhang Z
Bioorg Med Chem; 2013 Jan; 21(1):11-20. PubMed ID: 23206987
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
[TBL] [Abstract][Full Text] [Related]
20. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
